<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04685798</url>
  </required_header>
  <id_info>
    <org_study_id>201912072</org_study_id>
    <nct_id>NCT04685798</nct_id>
  </id_info>
  <brief_title>Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT</brief_title>
  <official_title>Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a longitudinal study evaluating post-treatment changes in patients&#xD;
      with squamous cell carcinoma (SCC) of the neck using an innovative optimized&#xD;
      diffusion-weighted imaging (DWI) pulse sequence to identify more accurately recurrent tumors&#xD;
      as well as early non-responders to therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>All anonymized MRI studies will be blindly evaluated by at least two experienced neuroradiologists</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Apparent diffusion coefficient mean (ADCmean)</measure>
    <time_frame>2-3 weeks post-standard of care treatment</time_frame>
    <description>ADC=measure of the magnitude of diffusion (of water molecules) within tissue&#xD;
The primary tumor, suspicious lesion, and/or area of post-treatment change will be identified in anatomical images &amp; then outlined in the ADC sequence, excluding areas of cystic change and necrosis. If there are multiple lesions, only the dominant lesion with the lowest ADC will be used for analysis&#xD;
A histogram analysis method will examine the distribution of ADC values within each region of interest (ROI)&#xD;
ADCmean will describe distribution of ADC measurements in tumor/non-tumor tissues &amp; independent sample t-test will compare ADC measurements between the 2 groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent diffusion coefficient lowest value in a tumor (ADCmin)</measure>
    <time_frame>2-3 weeks post-standard of care treatment</time_frame>
    <description>ADC=measure of the magnitude of diffusion (of water molecules) within tissue&#xD;
The primary tumor, suspicious lesion, and/or area of post-treatment change will be identified in anatomical images &amp; then outlined in the ADC sequence, excluding areas of cystic change and necrosis. If there are multiple lesions, only the dominant lesion with the lowest ADC will be used for analysis&#xD;
A histogram analysis method will examine the distribution of ADC values within each region of interest (ROI)&#xD;
ADCmin will describe distribution of ADC measurements in tumor/non-tumor tissues &amp; independent sample t-test will compare ADC measurements between the 2 groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of non-responders to treatment as measured by DWI MRI as compared to the number of non-responders to treatment as measured by FDG PET/CT</measure>
    <time_frame>2-3 weeks post-standard of care treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>DWI MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-The patients will undergo an optimized research neck DWI MRI, up to 3 weeks post-treatment and then a standard-of-care 3-month post-treatment FDG PET/CT examination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diffusion-weighted imaging magnetic resonance imaging</intervention_name>
    <description>The research MRI study of the head and neck will be performed on a Siemens 3T MRI Scanner system</description>
    <arm_group_label>DWI MRI</arm_group_label>
    <other_name>DWI MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically-proven newly diagnosis or recurrence as indicated by tissue diagnosis&#xD;
             of T3 or T4 squamous cell carcinoma of the head and neck&#xD;
&#xD;
          -  Must have had or be scheduled for standard-of-care surgical resection, radiation,&#xD;
             and/or chemo-radiation of the diagnosed squamous cell carcinoma of the head and neck&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Patient must be able to understand and willing to sign a written informed consent&#xD;
             document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to MRI, including:&#xD;
&#xD;
               -  MRI-incompatible implantable devices&#xD;
&#xD;
               -  severe claustrophobia; and&#xD;
&#xD;
          -  Pregnant and/or breastfeeding, with women of childbearing potential having a negative&#xD;
             urine or serum pregnancy test&#xD;
&#xD;
          -  Lack of standard of care (SOC) PET/CT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gloria J Guzman Pérez-Carrillo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gloria J Guzman Pérez-Carrillo, M.D.</last_name>
    <phone>314-362-5950</phone>
    <email>guzman.gloria@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria J Guzman Pérez-Carrillo, M.D.</last_name>
      <phone>314-362-5950</phone>
      <email>guzman.gloria@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Gloria J Guzman Pérez-Carrillo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Parsons, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Zevallos, M.D., MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Gerndt, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robin Haverman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dorina Kallogjeri, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hongyu An, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

